Immunologic and pharmacologic concepts of monoclonal antibodies

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.

Original languageEnglish (US)
Pages (from-to)166-186
Number of pages21
JournalSeminars in Nuclear Medicine
Volume19
Issue number3
DOIs
StatePublished - 1989

Fingerprint

Monoclonal Antibodies
Antibody-Producing Cells
Antibody Affinity
Recombinant DNA
Cell Fusion
Antibody Formation
Immunoglobulins
Pharmacology
Technology
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Immunologic and pharmacologic concepts of monoclonal antibodies. / Zuckier, Lionel S.; Rodriguez, Lorna D.; Scharff, Matthew D.

In: Seminars in Nuclear Medicine, Vol. 19, No. 3, 1989, p. 166-186.

Research output: Contribution to journalArticle

@article{1ecb8bdbc29940ad986801b3d718fe50,
title = "Immunologic and pharmacologic concepts of monoclonal antibodies",
abstract = "While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.",
author = "Zuckier, {Lionel S.} and Rodriguez, {Lorna D.} and Scharff, {Matthew D.}",
year = "1989",
doi = "10.1016/S0001-2998(89)80012-1",
language = "English (US)",
volume = "19",
pages = "166--186",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunologic and pharmacologic concepts of monoclonal antibodies

AU - Zuckier, Lionel S.

AU - Rodriguez, Lorna D.

AU - Scharff, Matthew D.

PY - 1989

Y1 - 1989

N2 - While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.

AB - While monoclonal antibodies have solved many of the difficulties of using immunologic reagents for radioimmunodiagnosis and therapy, in the 13 years since their introduction a number of persistent problems remain, most notably a low yield of antibody-producing cells from the fusion process, difficulty in obtaining high-affinity antibodies, and the potential immunogenicity of murine immunoglobulins (Igs). Several solutions are under development, including fusion techniques that enrich for cells producing desired antibodies, production of human-mouse chimeric antibodies by recombinant DNA technology, and the generation of human monoclonal antibodies by promising new approaches. Until these upcoming methodologies are established, and to better direct their development and application, a sound under-standing of the pharmacology of presently available native and modified monoclonal antibodies is crucial. Although much has been already determined in this area, a great deal of further clarification remains necessary.

UR - http://www.scopus.com/inward/record.url?scp=0024698430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024698430&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(89)80012-1

DO - 10.1016/S0001-2998(89)80012-1

M3 - Article

C2 - 2669128

AN - SCOPUS:0024698430

VL - 19

SP - 166

EP - 186

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -